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RESEARCH ARTICLE 
Summary. Orally ingested probiotic bacteria are able to modulate the immune sys-
tem. However, differences exist in the immunomodulatory effects of different probi-
otic strains. Moreover, different regulatory effects, which depend on the health status
of the consumer, have been identified. This work describes a randomized, double-
blind, placebo-controlled human clinical trial to investigate the immune effects on
healthy people of a fermented product containing two new probiotic strains, Lacto-
bacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, which was
compared with another fermented product, a standard yogurt. Consumption of either
the new product or yogurt increased the proportion of phagocytic cells, including
monocytes and neutrophils, as well as their phagocytic activity. However, combina-
tion of the product containing the strains L. gasseri CECT 5714 and L. coryniformis
CECT 5711 also induced an increase in the proportion of natural killer (NK) cells and
in IgA concentrations. The effects were higher after two weeks of treatment than after
4 weeks, which suggests regulation of the immune system. In addition, the new prod-
uct enhanced immunity in the participants to a greater extent than did the control stan-
dard yogurt. [Int Microbiol 2006; 9(1):47-52]
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Introduction
Endogenous microbiota has a modulatory effect on the mucos-
al and systemic immune response. In fact, the type of bacteria
that colonize the intestine in newborns determines immuno-
modulation of the naive immune system [9]. The usual compo-
nents of the gut microbiota, such as lactobacilli, modulate the
immune system, causing, for instance, host resistance to infec-
tions, atopy, and gut inflammation [13,26,30]. While the
immune mechanisms of such bacteria, called probiotics, have
not been totally defined, several clinical trials have studied the
effects of probiotics consumption on human health. Most of
these trials evaluated the effect of probiotics on patients suffer-
ing from diarrhea, Helicobacter pylori infections, intestinal
inflammation, or atopy [4,10,14], and the results varied great-
ly. However, few data are available regarding the immune
effects of probiotics in healthy people, the main target of such
products currently on the market.
In a previous study, we reported that breast milk of healthy
women is a major source of lactic acid bacteria to the infant
gut, and that Lactobacillus gasseri is among the predominant
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species [18]. The microbiota of newborns could be responsible
for some of the health benefits observed in breast-fed com-
pared to formula-fed infants [3,5,34]. A breast-milk strain of L.
gasseri (CECT 5714) was selected based on its particular in
vitro probiotic properties [19]. We also selected L. coryniformis
CECT 5711 from an artisan goat’s milk cheese; this strain
exhibits peculiar probiotic properties, including the production
of reuterin and cobalamin [20]. Also, in a randomized, double-
blind, placebo-controlled human clinical trial, we investigated
the effects of a fermented product containing the probiotic
strains L. gasseri CECT 5714 and L. coryniformis CECT 5711
on the intestinal function of healthy adults and compared them
with the effects of a standard probiotic with a long consumption
history and demonstrated beneficial effects [1,21,25,29]. An
increase in the concentration of fecal lactic acid bacteria and a
beneficial effect on the bowel function of healthy adults volun-
teers consuming the new probiotic strain was observed. In this
work, we describe the effects of the new probiotic strains on the
immune system of healthy adults in that clinical trial.
Material and methods 
Design of the trial. Thirty healthy adult human volunteers (15 females
and 15 males) ranging in age from 23 to 43 years old were included in the study.
Exclusion criteria and the protocol followed was described elsewhere [25].
Collection and analysis of fecal samples. After an overnight
fast lasting at least 10 h, blood samples were withdrawn using EDTA-con-
taining vacutainers (S-Monovette, Sarstedt, Germany) from the volunteers
just before and after the treatment period. The proportion of neutrophils was
analyzed using a Symex F-800 counter (Coulter Electronic, Luton, London,
UK). Major leukocyte subset phenotypes were counted in EDTA-treated
whole-blood samples by flow cytometry on a FACScalibur (Becton
Dickinson, Oxford, UK) system and using the following fluorochrome-con-
jugated monoclonal antibodies (Becton Dickinson): anti-CD3+, -CD19+,
-CD4+, -CD8+, -CD45RO+, -CD56+, -CD25+, -CD14+. The results were
expressed as the percentage of positively staining mononuclear cells. Fecal
samples were collected weekly, placed into pre-weighed bottles, and then
homogenized in a peptone-saline solution (100 mg/ml) within 12 h. 
Phagocytic activity. In vitro phagocytic activity was determined by
flow cytometry of whole-blood samples after the uptake of fluoresceinated
Escherichia coli [7]. One hundred ml of heparin-treated whole blood was
incubated at 37ºC for 10 min with 10 ml (108 colony-forming units, cfu) of
fluoresceinated bacteria. Erythrocytes were lysed with 100 ml of 4%
formaldehyde and 1 ml of cool water. Samples were centrifuged at 2200 ×g
for 5 min, suspended in 0.5 ml of 4% (w/v) formaldehyde in PBS, and ana-
lyzed by flow cytometry. The results were expressed as the percentages of
monocytes and granulocytes showing phagocytic activity. 
Total immunoglobulin and cytokines measurements. IgA,
IgG, and IgE concentrations in serum and total IgA concentration in feces
were measured by ELISA (Bethyl, Montgomery, TX, USA). Cytokine con-
centrations in sera were measured by ELISA (CytoSets, Biosource,
Camarillo, CA, USA). 
Statistical analysis. Data were analyzed using SPSS software (version
12.0, Chicago, IL, USA) as described in [25] for the Gaussian variables. 
Results
Clinical observations. None of the volunteers volun-
tarily left the study. Only one had to leave at the end of the
pre-test period, due to the use of antibiotics for treatment of
an oral bacterial infection not related to this study.
Leukocyte subsets and proportions. Flow cytomet-
ric analysis of the proportion of monocytes (CD14+ cells)
showed an increase after 2 weeks of consumption of either of
the fermented products, but the differences were statistically
significant only in the case of the group receiving the new pro-
biotic product. At the end of the treatment, the proportions of
monocytes were only slightly higher than the initial values
(Table 1). After 2 weeks of treatment, there was also a signifi-
cant increase in the neutrophil proportion in both groups, but
at the end of treatment it was maintained only in the new pro-
biotic group. The proportion of total lymphocytes and cells
staining positively for CD3+ (T lymphocytes), CD8+ (cytotox-
ic T lymphocytes), CD4+ (T-helper lymphocytes), CD19+ (B
lymphocytes), CD3+CD45RO+ (memory T lymphocytes),
CD4+CD25+ (suppressor T lymphocytes), and CD56+ (natu-
ral killer, NK, cells) were in the ranges of those for hematolog-
ically normal Caucasian adults (Table 1). However, a signifi-
cant decrease, more evident at the end of treatment, was detect-
ed in the proportions of lymphocyte and of CD3+ and CD19+
cells in both groups. Despite that decrease, we observed that
these values had increased during the two-week pretreatment
period, probably due to the absence of fermented product in
the diet before the treatment, and were normalized after con-
sumption of both fermented products (data not shown). The
most outstanding result was the significant increase in the pro-
portion of NK cells after 2 and 4 weeks of treatment in the
group that had ingested the new probiotic strains (Fig. 1). In
contrast, NK proportions in the control group decreased at the
end of treatment and were significantly lower than in the group
receiving the new probiotic preparation (Fig. 1). Subjects
receiving the latter were ranked and stratified depending on
their preintervention levels of NK cells into two groups: a
group with high preintervention values (above the mean +10%
of the preintervention proportion of NK cells) and a group with
medium/low preintervention values (below the mean +10% of
the preintervention proportion of NK cells). To study whether
the effect of treatment was related to the initial proportion of
NK cells, the relative increases in NK-cell proportions were
calculated. In the group receiving the new probiotic, changes
in NK-cell proportions occurred in volunteers who initially
had normal/low values, with percentage increases of 209.49 ±
8.92 and 133.29 ± 12.83, respectively, after 2 and 4 weeks of
treatment. By contrast, there was no increase in the proportion
of NK cells in subjects who had high initial values.
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Phagocytic activity. The percentages of both mononu-
clear and polymorphonuclear cells showing phagocytic activ-
ity in vitro increased significantly during the period in which
the two fermented products were consumed (Fig. 2).
Although the increase was higher in the group that had
ingested the new probiotic preparation, the differences
between the groups were not statistically significant.
Effects on cytokine expression pattern and
immunoglobulin production. The cytokines tumor
necrosis factor (TNF)-α, interleukin (IL)-12, IL-10 and IL-4
were measured in serum. In the group consuming the new
probiotic product, IL-10 and IL-4 increased significantly
after 2 weeks of treatment. However, at the end of the treat-
ment period, the IL-4 levels no longer differed from those at
the beginning of treatment, while IL-10 levels were higher,
but not significantly (Table 2). A significant increase in IgA
concentrations was measured in the blood of volunteers who
NEW PROBIOTIC STRAINS
Table 1. Percentage of white blood cell subsets. Results are expressed as mean ± s.e.m.
Control group Probiotic group
Week 0 Week 2 Week 4 Week 0 Week 2 Week 4
Monocytes (%) 07.29 ± 0.58 09.03 ± 1.26 08.11 ± 0.94 07.02 ± 0.53 11.00 ± 1.40* 08.45 ± 1.62
Neutrophils (%) 50.55 ± 1.75 57.48 ± 2.81* 54.28 ± 2.06 50.90 ± 1.98 57.34 ± 2.37** 58.66 ± 1.37**
Lymphocytes(%) 45.81 ± 0.93 37.49 ± 2.42* 42.50 ± 2.19 43.97 ± 1.81 37.13 ± 2.61** 38.13 ± 1.33*
T lymphocytes (%) 67.65 ± 2.33 64.95 ± 2.09 61.15 ± 2.87 62.90 ± 2.36 56.48 ± 2.68* 56.49 ± 2.64**
T helper (%) 37.56 ± 1.80 33.14 ± 1.89 36.68 ± 2.72 39.25 ± 1.43 36.75 ± 1.12 39.31 ± 1.62
T cytotoxic (%) 25.21 ± 1.73 25.45 ± 2.02 26.32 ± 2.41 23.74 ± 1.08 22.24 ± 1.40 23.33 ± 0.97
T suppressor (%) 17.52 ± 1.44 19.41 ± 2.09 16.15 ± 0.96 18.42 ± 1.36 18.54 ± 1.81 17.75 ± 1.36
T memory (%) 39.32 ± 2.33 39.28 ± 4.10 36.49 ± 2.82 35.10 ± 2.01 37.31 ± 2.69 32.36 ± 1.91*
B lymphocytes (%) 11.38 ± 1.62 11.01 ± 1.42 09.24 ± 1.70** 09.48 ± 0.72 08.74 ± 0.84 08.23 ± 0.71*
Statistically significant difference with respect to week 0: * p < 0.05, ** p < 0.01. 
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Fig. 1. Mean (±s.e.m.) of the percentage of lymphocytes staining positively
for CD56+ (natural killer cells) in the blood of volunteers who received the
new probiotic product (black bars) and in the control group (gray bars).
* Statistically significant difference (* p < 0.05) respect to week 0.
# Significant difference (p < 0.05) between control and treatment group.
Fig. 2. Monocytes and granulocytes were differentiated by size and com-
plexity by flow cytometer. Phagocytic activity of monocytes (A) and granu-
locytes (B) before and after 2 and 4 weeks of treatment is expressed as the
mean (± s.e.m.) of the percentage of leukocytes containing fluoresceinated
Escherichia coli after in vitro incubation of the bacteria with fresh blood.
Black bars, probiotic group; gray bars, control group. *, ** Statistically sig-
nificant difference (* p < 0.05, ** p < 0.01) respect to week 0.
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were given the new probiotic product (Table 3). In feces,
there was a slight increase in IgA levels, but it was not signif-
icant. Serum IgG levels remained stable in both groups
throughout the study. In addition, after 2 weeks there was a
significant decrease in the serum IgE levels of volunteers in the
new-probiotic group and in the control group; however, at the
end of treatment the decreases were not significant (Table 2).
Discussion
Modulation of the immune response is one of the most
acclaimed health benefits attributed to probiotic strains [6].
Previous studies in humans reported the effects of oral
administration of probiotic strains on innate and specific
immunity [2,31,32,37]. Although studies of the mechanisms
by which probiotics exert this immunomodulatory effect are
still in progress, recent data have shown differences in the
immunomodulatory effects of different probiotic strains.
Moreover, different regulatory effects have been detected in
healthy subjects and in patients with inflammatory diseases
[12]. These results suggest that the specific immunomodula-
tory properties of probiotic bacteria should be specifically
characterized on target populations.
Our results showed that the consumption of either the new
probiotic product or a standard yogurt preparation resulted in an
increase in phagocytic cells, including monocytes and neu-
trophils, and enhanced phagocytic activity. These results are
consistent with those of previous studies on other probiotic
strains [31,32]. Although the new probiotic strains seemed to be
more effective, consumption of the standard yogurt produced
similar results. In fact, the effect of L. delbrueckii subsp. bulga-
ricus on monocytes and macrophages function was previously
reported [29].
Monocytes and macrophages, together with dendritic
cells, play a crucial role in the innate immune response
against microbial antigens, which in turn leads to activation
of the adaptive immune system [15]. These cells recognize
conserved molecular patterns of bacterial components
through toll-like receptors (TLR), leading to activation of a
variety of transcription factors, which triggers cytokine pro-
duction [36]. The ability of these cells to recognize conserved
structures present in large groups of bacteria enables them to
effectively detect a wide range of pathogens, and this
response is strengthened even when the increase in the
phagocytic function is induced by non-pathogen bacteria,
such as those in probiotic preparations. NK cells are also
involved in the innate response and play a major role in rec-
ognizing and killing both virus-infected cells and tumor cells.
In our study, the percentage of NK cells increased in the new-
probiotic group but decreased in the control group. More-
over, the increase in the proportion of NK cells was restricted
to volunteers in the new-probiotic group that initially had
normal/low numbers of NK cells, while there was no change
in subjects with initially higher NK-cell counts. In elderly
people, in individuals with poor lifestyle habits, such as
OLIVARES ET AL.
Table 2. Cytokine concentrations in blood. Results are expressed as pg (mean ± s.e.m.) per ml of serum 
Control group Probiotic group 
Week 0 Week 2 Week 4 Week 0 Week 2 Week 4
TNF-α 38.49 ± 13.25 36.14 ± 13.14 37.49 ± 15.69 38.37 ± 9.24 46.57 ± 11.16 35.74 ± 11.54
IL-10 56.38 ± 27.03 60.71 ± 28.69 72.24 ± 35.68 64.27 ± 31.75 84.62 ± 39.29* 81.80 ± 54.25
IL-12 21.41 ± 5.57 23.17 ± 5.90 33.06 ± 9.40 21.43 ± 5.25 23.06 ± 5.78 22.03 ± 6.44
IL-4 30.96 ± 9.39 43.79 ± 17.52 47.27 ± 15.79 28.26 ± 9.93 37.96 ± 10.22* 25.7 ± 15.36
TNF, Tumor necrosis factor; IL, interleukin. Statistically significant difference with respect to week 0: * p < 0.05.
Table 3. Immunoglobulin concentrations in serum. Results are expressed as mean ± s.e.m.
Control group Probiotic group
Week 0 Week 2 Week 4 Week 0 Week 2 Week 4
IgA(mg/g feces) 200.94 ± 37.92 225.13 ± 73.20 214.66 ± 42.49 181.21 ± 37.33 214.95 ± 45.11 248.36 ± 55.91
IgA(mg/dl serum) 139.39 ± 16.98 151.89 ± 30.32 126.51 ± 23.23 137.08 ± 20.37 158.12 ± 19.51 159.29 ± 23.00*
IgG(mg/dl serum) 1045.5 ± 169.0 1317.1 ± 154.4 1141.0 ± 118.8 1144.1 ± 203.6 1303.2 ± 277.5 1114.5 ± 169.6
IgE(mg/dl serum) 190.40 ± 39.26 161.48 ± 35.25* 195.33 ± 52.95 192.58 ± 48.07 147.64 ± 39.61** 169.53 ± 39.21
Statistically significant difference with respect to week 0: * p < 0.05, ** p < 0.01.
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smoking, or in those with mental stress, a decrease in the pro-
portions of NK cells has been reported [11,24,33]. Since pro-
biotics seem to offer benefits to people whose health could be
improved, they could also be effective in people with typical-
ly low levels of NK function. The positive effect of probi-
otics on NK cells has been previously reported for other lac-
tobacillus strains [8,23], and their stimulation of the immune
system and antitumor effects in animal models of cancer
have been reported [17,35]. The lack of an increase in the pro-
portion of NK cells in the control group may have been due to
a lower adherence of the starter strain, L. delbrueckii subsp. bul-
garicus, to both the gut mucosa and Peyer’s patches, which
would have made contact with immune cells difficult [27]. In
fact, we did not detect an increase in fecal lactic acid bacteria in
the control group [25]. Therefore, the consumption of the new
probiotic product might have increased the innate immune
response. Innate immunity is activated very quickly after infec-
tion when acquired immunity has not yet developed. Thus the
improvement of innate immunity would strengthen the
response against possible infections or cell transformations.
The effects were in generally higher after 2 weeks of treat-
ment than after 4 weeks, suggesting that they involved regu-
lation of the immune system. The effect of treatment on the
response capability against stimuli occurring weeks after the
end of the treatment finished is currently being investigated.
The level in serum of the main cytokines involved in the
regulation of the immune response were also analyzed in
order to determine whether the acquired immune response
was also affected. The increase in IL-10 and IL-4 concentra-
tions suggests a role for a Th2 response. However, the serum
IgE concentration was lower in the new-probiotic group than
in controls, which suggests that other cytokines should be
involved in IgE switching. IgE is involved in the allergy
processes, so a decrease in the levels of this immunoglobulin
could be beneficial for allergic subjects. In fact, the benefi-
cial effect of a strain of L. rhamnosus in the prevention of
atopy has been reported [14,15].
The increase in Th2 cytokines, including IL-4, could also
affect IgA switching. In fact, a significant increase in the total
IgA concentration in serum was detected, but only in the group
that received the new probiotic product. IgA is the main
immunoglobulin involved in mucosal defense. Thus, an
increase in its concentration enhances its protection against
pathogens. It has been reported that increases in IgA are related
to the anti-infectious properties of probiotics in the treatment of
diarrheal disease [37,38].
Although both probiotic products—the new preparation and
the control yogurt—induced immune effects, consumption of
the former, containing two lactobacilli strains, L. gasseri
(CECT 5714) and L. coryniformis (CECT 5711), enhanced
immunity in healthy people to a greater extent than the stan-
dard yogurt consumption. 
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OLIVARES ET AL.
El consumo de dos nuevas cepas probióticas,
Lactobacillus gasseri CECT 5714 y Lacto-
bacillus coryniformis CECT 5711, estimula 
el sistema inmunitario de individuos sanos
Resumen. La ingestión oral de bacterias probióticas puede modular el sis-
tema inmunitario. Sin embargo, existen diferencias en los efectos inmuno-
moduladores de diferentes cepas probióticas. Además, se han identificado
distintos efectos reguladores, que dependen del estado de salud del consumi-
dor. Este trabajo describe un ensayo clínico aleatorizado, con ocultación
doble (double blind) y con control de placebo llevado a cabo en humanos
para estudiar los efectos inmunitarios del consumo de un producto fermen-
tado que contiene dos nuevas cepas probióticas, Lactobacillus gasseri CECT
5714 y Lactobacillus coryniformis CECT 5711, comparados con los efectos
producidos por otro producto fermentado, un yogurt clásico. El consumo del
nuevo producto o del yogurt clásico aumentó la proporción de células fago-
citarias, como monocitos y neutrófilos, así como su actividad fagocitaria. Sin
embargo, la combinación del producto que contenía las cepas L. gasseri
CECT 5714 y L. coryniformis CECT 5711 indujo además un aumento en la
proporción de linfocitos citolíticos natuales (células NK) y en las concentra-
ciones de IgA. Estos efectos fueron más acusados después de dos semanas de
tratamiento que después de 4 semanas, lo que sugiere una regulación del sis-
tema inmunitario. Además, el nuevo producto reforzó la inmunidad en las
personas que participaron en el ensayo más que el yogur clásico usado como
control. [Int Microbiol 2006; 9(1):47-52]
Palabras clave: Lactobacillus gasseri · Lactobacillus coryniformis ·
probióticos · ensayo clínico en humanos · respuesta inmunitaria 
O consumo de duas novas cepas probióticas,
Lactobacillus gasseri CECT 5714 e Lacto-
bacillus coryniformis CECT 5711, estimula o
sistema imunitário de indivíduos sãos 
Resumo. A ingestão oral de bactérias probióticas pode modular o sistema
imunitário. No entanto, existem diferenças nos efeitos imunomoduladores
de diferentes cepas probióticas. Além  disto, foram detectados diferentes
efeitos reguladores dependentes do estado de saúde do consumidor. Este
trabalho descreve um ensaio clínico aleatorizado, com ocultação dupla
(double blind) e com controle de placebo levado a cabo em humanos para
estudar os efeitos imunitários do consumo de um produto fermentado que
contém duas novas cepas probióticas, Lactobacillus gasseri CECT 5714 e
Lactobacillus coryniformis CECT 5711, comparados com os efeitos
produzidos por outro produto fermentado, um iogurte clássico. O consumo
tanto do novo produto como do iogurte clássico aumentou a proporção de
células fagocitárias, como monócitos e neutrófilos, assim como sua
atividade fagocitária. No entanto, a combinação do produto que continha as
cepas L. gasseri CECT 5714 e L. coryniformis CECT 5711 induziu também
um aumento na proporção de linfócitos citolíticos natuales (células NK) e
nas concentrações de IgA. Estes efeitos foram mais aguçados após duas
semanas de tratamento do que após 4 semanas, o que sugere uma regulação
do sistema imunitário. Além disto, o novo produto reforçou de forma mais
acentuada a imunidade das pessoas que participaram do ensaio do que o
iogurte clássico usado como controle.  [Int Microbiol 2006; 9(1):47-52]
Palavras chave: Lactobacillus gasseri · Lactobacillus coryniformis ·
probióticos · ensaio clínico em humanos · resposta imunitária
